



Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate
	6,232,326	05/15/01	Nelson	514	336	
	5,430,039	07/04/95	Roberts-Lewis et al.	514	297	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclasses	Translation Yes/No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

		Aisen, P.S., "Multicenter trial of hydroxychloroquine," CRISP (1998) abstract only
		Allison, J. L., O'Brien, R. L. and Hahn, F. E., (1965), "Nature of the deoxyribonucleic acid-chloroquine complex," <i>Antimicrob Agents Chemother.</i> 5:310-314
		Amabeoku, G. J. and Chikuni, O. (1992), "Involvement of GABAergic mechanisms in chloroquine-induced seizures in mice," <i>Gen Pharma</i> , 23(2):225-229
		Amabeoku, G. J. (1994), "Some behavioral effects of chloroquine in rats suggesting dopaminergic activation," <i>Indian J Med Res</i> , 99: 87-94
		Amabeoku, G. J. and Chikuni, O. (1992), "Chloroquine-induced seizures in mice: the role of dopaminergic system," <i>Br J Pharmacol</i> , 106: 54P, abstract only
		Amabeoku, G. J. and Chikuni, O. (1992), "Chloroquine-induced seizures in mice: the role of monoaminergic mechanisms," <i>Eur J Neuropsychopharm</i> , 3: 37-44
		Augustijns, P. and Verbeke, N. (1992), "Stereoselectivity in the disposition of chloroquine and desethyl-chloroquine in rabbits," <i>Arzneimittelforschung</i> , 42(6):825-828
		Augustijns, P., Geusens, P. and Verbeke, N. (1992), "Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis," <i>Eur J Clin Pharmacol</i> , 42:429-433
		Batchelor, P. E. et al. (1999), "Activated macrophages and microglia induced dopaminergic sprouting in the injured striatum and express brain derived neurotrophic factor and glial cell line derived neurotrophic factor," <i>J Neurosci</i> , 19(5):1708-1716

2/21/05

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Batchelor, P. E. et al. (1999), "Activated macrophages and microglia induced dopaminergic sprouting in the injured striatum and express brain derived neurotrophic factor and glial cell line derived neurotrophic factor," <i>J Neurosci</i> , 19(5):1708-1716
	Ben-Shachar, D. et al. (1995), "Dopamine neurotoxicity inhibition of mitochondrial respiration," <i>J Neurochem</i> , 64:718-723
	Bergmann, K. J., et al. (1986), "Parkinson's disease and long term levodopa therapy," <i>Adv Neurol</i> , 45:463-467
	Bhakar, A. L., et al. (2002), "Constitutive nuclear factor kappa B activity is required for central neuron survival," <i>J Neurosci</i> , 22(19):8466-8475
	Bodnar, R. J., et al. (1990), "Proglumide selectively potentiates supraspinal mu 1 opioid analgesia in mice," <i>Neuropharmacol</i> , 29(5):507-510
	Brockmoller, J., et al. (2002), "The importance of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment," <i>Clin Pharmacol & Therap</i> , 72(4):438-452
	Brooks, D. J. and Samuel, M. (2000), "The effects of surgical treatment of parkinson's disease and tremor: articles" <i>Am Acad Neurol</i> , 55(12):S52-S59
	Brooks, D. J., et al. (2000), "Neuroimaging of dyskinesia," <i>Ann Neurol</i> , 47(suppl 1):S154-S159
	Buszman, E., et al. (1984), "Electron spin resonance studies of chloroquine-melanin complexes," <i>Biochem Pharmacol</i> , 33(1):7-11
	Cadet, J. L. and Kahler, L. A. (1989), "Free radical mechanisms in schizophrenia and tardive dyskinesia," <i>Neurosci Behav Rev</i> , 18(4):457-467
	Carta, A., et al. (2002), "Differential regulation of GAD67, enkephalin and dynorphin mRNA by chronic-intermittent l-dopa and A _{2a} receptor blockade plus l-dopa in dopamine-denervated rats," <i>Synapse</i> , 44:166-174
	Chang, K. J., et al. (1982), "Opioid peptides induce reduction of enkephalin receptors in cultured neuroblastoma cells," <i>Nature</i> , 296:446-448
	Chase, T. N. et al. (1986), "Fluctuation in response to chronic levodopa therapy pathogenetic and therapeutic considerations," <i>Adv Neurol</i> , 45:477-480
	Chen, F. Lu et al. (1997), "Calpain contributes to silica induced I kappa B-alpha degradation and nuclear factor-kappa B activation," <i>Arch Biochem Biophysics</i> , 342(2):383-388
	Chen, F. Lu et al. (1997), "Calpain contributes to silica induced I kappa B-alpha degradation and nuclear factor-kappa B activation," <i>Arch Biochem Biophysics</i> , 342(2):383-388
	Cheng, N. et al. (1996), "Differential neurotoxicity induced by l-dopa and dopamine in cultured striatal neurons," <i>Brain Res</i> , 743(1-2):278-283
	Chiodo, L. A. and Bunney B. S. (1983), "Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons," <i>J Neurosci</i> , 3(8):1607-1619
	Chugani, D. C. et al. (1988), "In vivo [³ H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization," <i>J Cereb Blood Flow & Metab</i> , 8(3):291-303
	Cohen, S. N. and Yielding, K. L., (1965), "Inhibition of DNA and RNA polymerase reactions by chloroquine," <i>Proc Natl Acad Sci</i> , 54(2):521-527.

Lucretia C. Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Coleman, T. et al., "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is n-demethylated by cytochromes P450 2D6, 1A2 and 3A4 -Implications for susceptibility to Parkinson's Disease," <i>J. Pharm. And Exp. Therapeutics</i> , 277(2):685-690
	Conley, R. R., and Buchanan, R. W. (1997), "Evaluation of treatment resistant schizophrenia," <i>Schizo Bull</i> , 23(4):663-674
	Cooper, A. and Mitchell, I. (1995), "Fos immuno-positive neurons in the STN following reversal of Parkinson's disease symptoms by antagonism of excitatory amino acid transmission in the entopeduncular nucleus of the monoamine depleted rat," <i>Neurosci Let</i> , 201(3):251-254
	Dahl, M-L, "Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing," <i>Clin Pharmacokinet</i> , 41(7):453-470
	D'Amato, R. J. et al. (1987), "Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to neuromelanin," <i>J Neurochem</i> , 48(2):653-658
	Davis, G.C. et al. (1979), "Chronic parkinsonism secondary to intravenous injection of meperidine analogues," <i>Psych Res</i> , 1:249-254
	Deutch, A. Y. (1993), "Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and parkinson's disease," <i>J Neural Trans</i> , 91(2-3):197-221
	Doss, R. C. et al. (1981), "Recovery of β -adrenergic receptors following long term exposure of astrocytoma cells to catecholamine," <i>J Biol Chem</i> , 258:12281-12286
	Egan, M. F. et al. (1997), "Treatment of tardive dyskinesia," <i>Schizo Bull</i> , 23(4):583-609
	Egan, M. F. et al. (1996), "Pharmacological and neurochemical differences between acute and tardive viscous chewing movements induced by haloperidol," <i>Psychopharmacol</i> , 127:337-345
	Elbert, M.H et al. (1984), "Selective neurotoxic effects of n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in subhuman primates and man a new animal model of parkinson's disease," <i>Psychopharmacol Bull</i> , 20(3):548-553
	Essien, E. E. and Ette, E. I., (1986), "Effects of chloroquine and didesethylchloroquine on rabbit myocardium and mitochondria," <i>J Pharm Pharmacol</i> , (38):543-546
	Essien, E. E. et al. (1989), "Chloroquine disposition in hypersensitive subjects and its significance in chloroquine-induced pruritus," <i>Eur J of Drug Metab and Pharmacokinet</i> , 14(1):71-77
	Ette, E. I. and Essien, E. E. (1986), "Neuromuscular weakness and ultrastructural damage produced by desethylated metabolites of chloroquine and the reversal by calcium," <i>West African J of Anatomy</i> 1(1):5-15
	Feigenbaum, P. E. and Fakahny, E. E. (1984), "Short term regulation of muscarinic acetylcholine receptor grinding in cultured nerve cells," <i>Res Commum Chem Pathol Pharmacol</i> , 43:519-522
	Frackiewicz, E. J. et al. (2002), "Brasofensine treatment for parkinson's disease in combination with levodopa/carbidopa," <i>Ann Pharmacother</i> , 36(2):225-230
	Fuller R. W. and Hemrick, S. K. (1985), "Effects of amfonelic acid α -methyltyrosine, Ro4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice," <i>Res Comm Chem Ophthalmol Pharmacol</i> , 48(1):17-25

Wayne

C. Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Furukawa, N. et al. (2001), "Endogenously released dopa is causal factor for glutamate release and resultant delayed neuronal cell death by transient ischemia in rat striata," <i>J Neurochem</i> , 76(3):815-824
	Geula, C. et al. (1994), "Cholinesterase activity in the plaques tangles and angiopathy of Alzheimer's disease does not emanate from amyloid," <i>Brain Res</i> , 644(2):327-630
	Glazer, W. M. et al. (1993), "Predicting the long-term risk of tardive dyskinesia in out-patients maintained on neuroleptic medications," <i>J Clin Psych</i> , 54(4):133-139
	Goodman, R. and Snyder, H. (1982), "K-opiate receptors localized by autography to deep layers of cerebral cortex: relation to sedative effects," <i>Proc Natl Acad Sci USA</i> , 79:5703-5707
	Goshima, Y. et al. (1993), "L-dopa induces Ca(2+)-dependent and tetrodotoxin-sensitive release of endogenous glutamate from rat striatal slices," <i>Brain Res</i> , 617(1):167-170
	Herrero, M. T. et al. (1996), "Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum," <i>Am Acad Neurol</i> , 47(1):219-224
	Hillier, C. E. et al. (Feb. 1999), "Thalamotomy for severe antipsychotic induced tardive dyskinesia and dystonia," <i>J. Neurol. Neurosurg. Psychiatry</i> 66:250-251
	Hirsch, E. (2000), "Nigrostriatal system plasticity in parkinson's disease: effect of dopaminergic denervation and treatment," <i>Ann Neurol</i> , 47(suppl 1):S155
	Hughes, N. et al. (1998), "Kappa-opioid receptor agonists increase locomotor activity in the monoamine depleted rat model of parkinsonism," <i>Mov Disord</i> , 13(2):228
	Iravan, M. M. et al. (2001), "GDNF reverses priming for dyskinesia in MPTP-treated, L-dopa primed common marmosets," <i>Euro J Neurosci</i> , 13(3):597-608
	Iverson, L.L. and Kelly, J.S. (1975), "Uptake and metabolism of γ -aminobutyric acid by neurons and glial cells," <i>Biochem Pharmacol</i> , 24:993-998
	Jarosinski, K. W. et al. (2001), "Specific deficiency in nuclear factor κ B activation in neurons of the central nervous system," <i>Lab Invest</i> , 81(9):1275-1288
	Jenner, P. (2000), "Factors influencing the onset and persistence of dyskinesia in MPTP treated primates," <i>Ann Neurol</i> , 47(suppl 1):S90-S104
	Jenner, P. (2002), "Pharmacology of dopamine agonists in the treatment of Parkinson's disease," <i>Am Acad Neurol</i> , 58(4):suppl 1 S1-S8
	Jindal, M. N. et al. (1960), "Local anesthetic action of antimalarials (chloroquine and amodiaquine)" <i>Arch Int Pharmacodyn</i> 127:132-140
	Jindal, M. N. (1970), "Adrenergic neurone blockade with chloroquine and amodiaquine," <i>Br J Med</i> , 58(8):1050-1056
	Johansson, P. E. et al. (1990), "Neuropeptide changes in a primate model (<i>cebus apella</i>) for tardive dyskinesia," <i>Neurosci</i> , 37(2):563-567
	Kane, J.M., "Tardive dyskinesia: epidemiological and clinical presentation," (1995) <i>Psychopharmacology: The Fourth Generation of Progress</i> , 1485-1495
	Kingsbury, A. E. et al. (1998), "DNA fragmentation in human substantia nigra: apoptosis or perimortem effect?" <i>Mov Disord</i> , 13(6):877-884
	Klawans, H. and Shenker, D. (1970), "Theoretical implications of the use of L-dopa in parkinsonism," <i>Acta Neurol Scand</i> , 46:409-441
	Klawans, H. L. (1973), "The pharmacology of tardive dyskinesias" <i>Am J Psych</i> , 130(1):82-86.

loghe c for

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Kure, S. et al. (1991), "Glutamate triggers internucleosomal DNA cleavage in neural cells," <i>Biochem & Biophysical Res Comm</i> , 179(1):39-45
	Kurnick, N. B. and Radcliffe, I. E. (1962), "Reaction between DNA and quinacrine and other antimalarials," <i>J Lab & Clin Med</i> , 60(4):669-688
	Ladipo, G. O. et al. (1983), "Complete heart block in chronic chloroquine poisoning," <i>Int J Cardiol</i> , 4:198-200
	Lang, A. E. (2000), "Surgery for levodopa induced dyskinesias," <i>Ann Neurol</i> , 47(suppl 1): S193-S202
	Langston, J.W., (1986) "MPTP-induced Parkinsonism: how good a model is it?" <i>Recent Dev. In Parkinson's Disease</i> , 119-126
	Law, P. Y. et al. (1984), "Down-regulation of opiate receptor in neuroblastoma x glioma NG 108-15 hybrid cells," <i>J Biol Chem</i> , 259(14):4096-4104
	Lee, H. J. et al. (2001), "Anti-apoptotic role of NF-kappaB in auto-oxidized dopamine induced apoptosis of PC12 cells," <i>Journal of Neurochemistry</i> , 76(2):602-609
	Lieberman, J. A. et al. (1997), "Neurochemical sensitization in the pathophysiology of schizophrenia deficits and dysfunction in neuronal regulation and plasticity," <i>Neuropsychopharmacology</i> , 17:205-229
	Lim, L. Y. and Go, M. L. (1986), "The anticholinesterase activity of mefloquine," <i>Clin Exp Pharmacol Physiol</i> , 13(6):527-531
	Lindfors, N. (1993), "Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum," <i>Prog Neurol Psychopharmacol & Biol Psych</i> , 17(6):887-903
	Lipsky, R. H. et al. (2001), "Nuclear factor kappaB is a critical determinant in N-methyl-D-aspartate receptor mediated neuroprotection," <i>J Neurochem</i> , 78(2):254-264
	Liu, L. et al. 1990), "Interactions of chloroquine with benzodiazepine, gamma-aminobutyric acid and opiate receptors," <i>Biochem Pharma</i> , 41(10):1534-1536
	Lozano, A. M. et al. (2000), "Neuronal recording in parkinson's disease patients with dyskinesias induced by apomorphine," <i>Ann Neurol</i> , 47(suppl 1):S142-S146
	Luo, J. et al. (2002), "Subthalamic GAD gene therapy in a parkinson's disease rat model," <i>Science</i> , 298(5592):425-429
	Maeda, T. et al. (1997). "L-DOPA neurotoxicity is mediated by glutamate release in cultured rat striatal neurons," <i>Brain Res</i> , 771(1):159-162
	Maneuf, Y.P. et al., (1995) "Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease," <i>Brain Research</i> 683:102-108
	Mangelus, M. et al. (2001), "Involvement of nuclear factor kappa B in endothelin a receptor induced proliferation and inhibition of apoptosis," <i>Cell Mol Neurobiol</i> , (6):657-674
	Manson, A.J. et al., "High dose naltrexone for dyskinesias induced by levodopa," (2001) <i>J. Neurol. Neurosurg. Psychiatry</i> 70:554-556
	Martin, B. C. et al. (2001), "Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts," <i>Schizo Res</i> , 47(2-3):281-292

Wayne

C. J. J.

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Mavridis, M. and Besson, M. J. (1999), "Dopamine-opiate interaction in the regulation of neostriatal and pallidal neuronal activity as assessed by opioid precursor peptides and glutamate decarboxylase messenger RNA expression," <i>Neurosci</i> , 92(3):945-966
	Mitchell, I. J. et al. (1985), "Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus ceruleus," <i>Neurosci Lett</i> , 61:195-200
	Mitchell, I.J. and Carroll, C.B. (1997), "Reversal of Parkinson's disease symptoms in primates by antagonism of excitatory amino acid transmission, potential mechanisms of action," <i>Neurosci & Behav Res</i> , 21(4):469-475
	Mitchell, I. J. et al. (1994), "Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat," <i>Neurosci</i> , 63(1):1-5
	Mitchell, I. J. et al. (1985), "Subcortical changes in the regional uptake of [³ H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma aminobutyric acid antagonist into the subthalamic nucleus," <i>Brain</i> , 108(Pt.2):405-422
	Mitchell, I. J. et al. (1992), "A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain implications for the neural mechanisms that mediate dopamine agonist induced dyskinesia," <i>Brain</i> , (Pt 3):809-824
	Mitchell, I. J. et al.(1992), "Regional changes in 2-deoxyglucose uptake associated with neuroleptic induced tardive dyskinesia in the cebus monkey," <i>Mov Disord</i> , 7(1):32-37
	Mitchell, I. J. et al. (1986), "Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,5-tetrahydropyridine-induced parkinsonism in the monkey relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake," <i>Neurosci Lett</i> , 63:61-65
	Mitchell, I. J. et al. (1989), "Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,6-tetrahydropyridine," <i>Neurosci</i> , 32(1):213-226
	Miyachi, Y. et al. (1986), "Antioxidant action of antimalarials," <i>Ann Rheum Disease</i> , 45:244-248
	Morgenstern, H. and Glazer, W. M. (1993), "Identifying risk-factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications," <i>Arch Gen Psych</i> , 50:723-733
	Nandi, D. et al. (2002), "Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus," <i>Brain</i> , 125(11):2418
	Napier, T. C. and Mitrovic, I. (1999), "Opioid modulation of ventral pallidal inputs," <i>NY Acad Sci</i> , 877:176-201
	Nutt, J. G. (2000), "Clinical pharmacology of levodopa-induced dyskinesia," <i>Ann Neurol</i> , 47(suppl 1):S160-S166
	Obeso, J. et al. (2000), "Pathophysiology of levodopa-induced dyskinesias in parkinson's disease: problems with the current model," <i>Ann Neurol</i> , 47(suppl 1):S22-S34
	Ogura, M. and Kita, H. (2000), "Dynorphin exerts both postsynaptic and presynaptic effects in the globus pallidus of the rat," <i>J Neurophysiol</i> , 83(6):3366-3376

Wagner C. Jones

2/2/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Olanow, C.W. and Obeso, J. A. (2000), "Preventing levodopa induced dyskinesias," <i>Ann Neurol</i> , 47(suppl 1):S167-S178
	O'Shaughnessy, T.J. et al. (2003), "Acute neuropharmacologic action of chloroquine on cortical neurons in vitro," <i>Brain Res</i> , 959:280-286
	Osifo, N. (1979), "Drug-related transient dyskinesias," <i>Clin Pharma & Therap</i> , 25(6):767-771
	Ostermeier, A. et al. (2000), "Activation of mu- and delta-opioid receptors causes presynaptic inhibition of glutamatergic excitation in neocortical neurons," <i>Anesthesiol</i> , 93(4):1053-1063
	Pahl, J. L. et al. (1995), "Positron-emission tomography in tardive dyskinesia," <i>J Neuropsych</i> , 7:457-465
	Pandya, K. H. et al. (1968), "Mechanism of supersensitivity to catecholamines following chloroquine," <i>Arzneimittelforschung</i> , 18(7):786-790
	Perlmutter, J. S. et al. (1997), "MPTP induces dystonia and parkinsonism: clues to the pathophysiology of dystonia," <i>Am Acad Neurol</i> , 49(5):1432-1438
	Piccini, P. et al. (1997), "Alterations in opioid receptor binding in parkinson's disease patients with levodopa induced dyskinesias," <i>Ann Neurol</i> , 42(5):720-726
	Rascol, O. (2000), "Medical treatment of l-dopa induced dyskinesias," <i>Ann Neurol</i> , 47(suppl 1):S179-S188
	Rascol, O. et al. (1994), "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease," <i>Movement Disorders</i> , 9:437-440
	Reddy, R. D. and Yao, J. K. (1996), "Free Radical pathology in schizophrenia: a review," <i>Free Rad Pathol</i> , 33-43
	Richardson, P. J. (2001), "The adenosine A _{2A} receptor of the basal ganglia," <i>J Physiol</i> , 532(2):284-288
	Rinne, U. K. et al. (1990), "Positron emission tomography demonstrates dopamine D ₂ receptor supersensitivity in the striatum of patients with early parkinson's disease" <i>Mov Disord</i> , 5(1):55-59
	Rinne, U. K. et al. (1983), "Brain enkephalin receptors in parkinson's disease," <i>J Neural Transmiss, Supp.</i> 19:163-171
	Rodnitzky, R. L. (2002), "Drug-induced movement disorders," <i>Clin Neuropharmacol</i> , 25(3):142-152
	Ross, S. B. (1995), "Comparison of high-affinity binding of ³ H proadifen and ³ H (-)-cocaine to rat live membranes," <i>Pharmacol & Toxicol</i> , 76(2):141-145
	Rupp, A. and Keith, S. J. (1993), "The costs of schizophrenia: assessing the burden," <i>Psych Clin N Am</i> , 16:413-423
	Sarre, S. et al. (1997), "Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study," <i>J Neural Transm</i> , 104:1215-1228
	Schwartz, J. C. et al. (1993), "Dopamine D ₃ receptor: basic and clinical aspects," <i>Clin. Neuropharmacol.</i> 16(4):295-314
	Schwartz, J. C. et al. (1998), "Functional implications of multiple dopamine receptor subtypes: the D ₁ /D ₃ receptor coexistence," <i>Brain Research</i> , 26(2-3):236-242
	Seeman, P. and Kapur, S. (1997), "Clozapine occupies high levels of dopamine d2 receptors," <i>Life Sci</i> , 60(12):207-216
	Sheridan, R. et al. (1997), "Structural features of aminoquinolines necessary for antagonist activity against botulinum neurotoxin," <i>Toxicon</i> , 34(9):1439-1451

Wayne C. Jones

2/2/06














Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Shindou, T. et al. (2000), "Adenosine A _{2A} receptor enhances GABA _A -mediated IPSCs in the rat globus pallidus," 532(2):432-434
	Sodeyama, N. et al. (1999), "Association between butyrylcholin-esterase K variant and the Alzheimer neuropathological changes in apolipoprotein E (E4) carriers older than 75," <i>J Neurol Neurosurg Psych</i> , 67(5):693-694
	Sokoloff, P. et al. (1990), "Molecular cloning and characterization of a novel dopamine receptor (D ₃) as a target for neuroleptics," <i>Nature</i> , 347:146-151
	Stanford, I. M. and Cooper, A. J. (1999), "Presynaptic mu and delta opioid receptor modulation of GABA _A IPSCs in the rat globus pallidus in vitro," <i>J Neurosci</i> , 19(12):4796-4803
	Stern, Y. and Langston, J. W. (1985), "Intellectual changes in patients with MPTP-induced parkinsonism," <i>Neurol</i> , 35:1506-1509
	Sugaya, Y. et al. (2001), "Autoradiographic studies using L-[¹⁴ C]DOPA and - [³ H]DOPA reveal regional Na ⁺ -dependent uptake of the neurotransmitter candidate L-DOPA in the CNS," <i>Neurosci</i> , 104(1):1-14
	Szymanski, S. D. et al. (1996), "Vulnerability to tardive dyskinesia development in schizophrenia and ¹⁸ F-DG-PET study of cerebral metabolism," <i>Neuropsychopharmacol</i> , 15(6):567-575
	Tanaka, M. et al. (2000), "Novel alternative promoters of mouse glial cell line-derived neurotrophic factor gene," <i>Biochimica et Biophysica Acta</i> , 1494(1-2):63-74
	Tjalve, H. et al. (1981), "Studies on the binding of chlorpromazine and chloroquine to melanin in vivo," <i>Biochem Pharmacol</i> , 30(13):1845-1847
	Tseng, L. and Collins, K. (1991), "Involvement of epsilon and kappa opioid receptors in the inhibition of the tail flick response induced by phenazocine in the mouse," <i>J Exp Ther</i> , 259:330-336
	Wainer, I. W. et al. (1994), "Distribution of the enantiomers of hydroxychloroquine and its metabolites in ocular tissues of the rabbit after oral administration of racemic-hydroxychloroquine," <i>Chirality</i> 6:347-354
	Waldmeier, P. C. (2003), "Prospects for anti-apoptotic drug therapy of neurodegenerative diseases," <i>Nerv Sys Res</i> , 27(2):303-321
	Weber, S. M. et al. (2002), "Inhibition of mitogen activated protein kinase signaling by chloroquine," <i>J Immunol</i> , 168:5303-5309
	Weber, S. and Levitz, S. M. (2000), "Chloroquine interferes with lipopolysaccharide-induced TNF- α gene expression by nonlysosomal mechanisms," <i>J Immunol</i> , 163(3):1534-1540
	Weetman, J. and Anderson, I. M. (1997), "Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia," <i>J Neurol Neurosurg & Psych</i> , 63:417-418
	Weglicki, W. B. et al. (1993), "Modulation of cytokines and myocardial lesions by vitamin e and chloroquine in a Mg-deficient rat model," <i>Am. J. Cell Physiol</i> , 264(3):169-172
	Wiliak, D., Grattan, D., Heaspi, R. and Rahwan, R. (1981), "Synthesis and preliminary pharmacological evaluation of asymmetric chloroquine analogues," <i>J Med Chem</i> , 24(6):712-717
	Wolters, E. (1999), "Dopaminomimic psychosis in parkinson's disease patients: diagnosis and treatment," <i>Neurol</i> , 52(7):S10-S13

Wayne C. Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616/692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

	Yabe, T. et al.(2001), "NF κ B activation is required for the neuroprotective effects of pigment epithelium derived factor (PEDF) on cerebellar granule neurons," <i>J Bio Chem</i> , 276(46):43313-43319
	Yao, J. K. et al. (2001), "Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications," <i>CNS Drugs</i> , 15(4):287-310
	You, Z. B. et al. (1999), "Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides," <i>J Pharmacol & Exp Therap</i> 290(3):1307-1315
	Youdim, M. B. et al. (1994), "The enigma of neuromelanin in parkinson's disease substantia nigra," <i>J Neural Transm</i> , 43(suppl):113-122
	Yu, P. (2002), "Brasofensine neuro search," <i>Cur Opin Invest Drugs</i> , 1(4):504-508
	Yu, S. P. et al.(1999), "NMDA receptor mediated K ⁺ efflux and neuronal apoptosis," <i>Science</i> , 284(5412):336-339
	Zaheer, A. et al. (2001), "Effects of glia maturation factor over expression in primary astrocytes on MAP kinase activation, transcription factor activation and neurotrophin secretion," <i>Neurochem Res</i> , 26(12):1293-1299
	Zamir, N. et al. (1984), "Primate model of parkinson's disease: alterations in multiple opioid systems in the basal ganglia," <i>Brain Res</i> , 322(2):356-360
	Books
	Merritt's Textbook of Neurology, (1995), 9 th Ed, Williams & Wilkins, Baltimore, MD, "Movement disorders" pp. 713-730
	Sigma-Aldrich (2002), "Pain and Mechanisms of Analgesia," Catalog # FIO 356-500947 0112
	Electronic Resources
	"Chloroquine", "Sinemet" & "Levodopa" MicroMedex Healthcare Series, http://phantom.uchsc.edu/mdxcgi/di....SYS&SET=485440&SYS=1&T=358&D=1692
	"National Institute of Neurological Disorders and Stroke" Parkinson's disease: A research planning workshop, http://www.ninds.nih.gov/healinfo/diorder/parkinsol/pdreport/pftherapy.ntm
EXAMINER  DATE CONSIDERED 2/21/06	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

12/20/89



Examiner PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Jodi Nelson		GROUP 1614

U.S. PATENT DOCUMENTS

Exmr. Initial		Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclasses	Translation Yes/No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

		CHASE, T. M. et al., "Striatal mechanisms and pathogenesis of Parkinsonian signs and motor complications," (April 2000) <i>Annals of Neurology</i> 46(1):S122-S130
EXAMINER: DATE CONSIDERED 7/21/06		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes/No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

1	Abiose, A.K. et al., "Chloroquine-induced venodilation in human hand veins," (1997) <i>Clin. Pharm. & Therapeutics</i> 61(6):677-683
2	Antonini, A. et al., "Differential diagnosis of Parkinsonism with [¹⁸ F]Fluorodeoxyglucose and PET," (1998) <i>Movement Disorders</i> 13(2):268-274
2A	Ardueser, G.A. and Heim, H.C., "Some effects of chloroquine on oxidative processes in rat heart," (1967) <i>J. Pharmaceutical Sciences</i> 56(2):254-258
3	Baltzan, M. et al., "Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis," (1999) <i>Am. J. Respir. Crit. Care Med.</i> 160:192-197
4	Behl, C. et al., "Hydrogen peroxide mediates amyloid β protein toxicity," (1994) <i>Cell</i> 77:817-827
5	Ben-Shachar, D. and Youdim, M.B.H., "Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction," (1990) <i>J. Neural Transm.</i> 29:251-258
6	Ben-Shachar, D. et al., "The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons," (1991) <i>J. Neurochemistry</i> 56(4):1441-1444
7	Bergendi, L. et al., "Chemistry, physiology and pathology of free radicals," (1999) <i>Life Sciences</i> 64(18-19):1865-1874
8	Bitonti, A.J. et al., "Reversal of chloroquine resistance in malaria parasite <i>plasmodium falciparum</i> by desipramine," (1988) <i>Science</i> 241:1301-1303

Handwritten signatures and date:
Nelson C. Jones 2/2/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

8A	Booij, J. et al., "[¹²³ I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease," (1997) <i>J. Neurol. Neurosurg. Psychiatry</i> 62:133-140
9	Bowen, B.C. et al., "Proton MR spectroscopy of the brain in 14 patients with Parkinson's disease," (1995) <i>Am. J. Neuroradiology</i> 161(1):61-68
10	Burke, R.E., "Programmed cell death and Parkinson's disease," (1998) <i>Movement Disorders</i> 13(S1):17-23
11	Byrd, T.F. and Horowitz, M.A., "Chloroquine inhibits the intracellular multiplication of <i>Legionella pneumophila</i> by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens," (1991) <i>J. Clin. Investigation</i> 88(1):351-357
12	Carlsson, Arvid, "Development of new pharmacological approaches in Parkinson's disease," (1986) <i>Advances in Neurology</i> 45:513-518
13	Chan, P.C. and Bielski, B.H., "Enzyme-catalyzed free radical reactions with nicotinamide adenine nucleotides. II. Lactate dehydrogenase-catalyzed oxidation of reduced nicotinamide adenine dinucleotide by superoxide radicals generated by xanthine oxidase," (1974) <i>J. Biol. Chem.</i> 249(4):1317-1319
14	Cho, Y.W. and Aviado, D.M., "Pathologic physiology and chemotherapy of plasmodium berghei. IV. Influence of chloroquine on oxygen uptake of red blood cells infected with sensitive or resistant strains," (1968) <i>Exp. Parasitology</i> 23(2):143-150
15	Chrichton, R.R. and Ward, R.J., "Iron metabolism - new perspectives in view," (1992) <i>Biochemistry</i> 31(46):11255-11264
16	Chrischilles, E.A. et al., "The health burdens of Parkinson's disease," (1998) <i>Movement Disorders</i> 13(3):406-413
17	Cotzias, G.C. et al., "Melanogenesis and extrapyramidal diseases," (1964) <i>Chemistry in Medicine</i> 23:713-718
18	Culvenor, J.G. et al., "Non-A β component of Alzheimer's disease amyloid (NAC) revisited," (1999) <i>Am. J. Pathology</i> 155:1173-1181
19	Cummings, J.L., "Depression and Parkinson's Disease: A Review," (1992) <i>Am. J. Psychiatry</i> 149(4):443-454
20	Dailly, E. et al., "Chain-breaking antioxidants and ferriheme-bound drugs are synergistic inhibitors of erythrocyte membrane peroxidation," (1998) <i>Free Radical. Res.</i> 28(2):205-214

Wayne C. Jones 2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

21	D'Amato, R.J. et al., "Selectivity of the Parkinsonian neurotoxin MPTP: toxic metabolite MPP ⁺ binds to neuromelanin," (1986) <i>Science</i> 231:987-989
22	D'Amato, R.J. et al., "Evidence for neuromelanin involvement in MPTP-induced neurotoxicity," (1987) <i>Nature</i> 327:324-326
23	Davison, A.J. and Gee, P., "Redox state of cytochrome C in the presence of the 6-hydroxydopamine/oxygen couple: oscillations dependent on the presence of hydrogen peroxide or superoxide," (1984) <i>Arch. Biochem. and Biophysics</i> 233(2):761-771
24	Debing, I. et al., "Melanosome binding and oxidation-reduction properties of synthetic L-dopa-melanin as in vitro tests for drug toxicity," (1988) <i>Mol. Pharmacology</i> 33(4):470-476
25	De Duve, C. et al., "Lysosomotropic agents," (1974) <i>Biochem. Pharm.</i> 23:2495-2531
26	Deepalakshmi, P.D. et al., "Effect of chloroquine on rat liver mitochondria," (1994) <i>Indian J. Exp. Biology</i> 32(11):797-799
27	De Feo, P. et al., "Chloroquine reduces whole body proteolysis in humans," (1994) <i>Am. J. Physiology</i> 267:E183-E186
28	Dethy, S. et al., "Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in Parkinsonism," (1998) <i>Movement Disorders</i> 13(2):275-280
29	Dexter, D.T. et al., "Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease," (1989) <i>J. Neurochem.</i> 42(2):381-389
30	Di Monte, D.A. et al., "Astrocytes as the site for bioactivation of neurotoxins," (1996) <i>NeuroToxicology</i> 17(3-4):697-704
31	Farid, M.A., "The malaria campaign - why not eradication?" (1998) <i>World Health Forum</i> 19:417-427
32	Fridovich, I., "Superoxide dismutases," (1975) 147-159
33	Fukushima, T. et al., "Radical formation site of cerebral complex I and Parkinson's disease," (1995) <i>J. Neuroscience Res.</i> 42:385-390
34	German, D.C. et al., "1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced Parkinsonian syndrome in <i>macaca fascicularis</i> : which midbrain dopaminergic neurons are lost?" (1988) <i>Neuroscience</i> 24(1):161-174
35	Ghigo, D. et al., "Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells," (1998) <i>J. Clin. Invest.</i> 102(3):595-605

Lynne C. Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

36	Gibb, W.R.G. and Lees, A.J., "Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease," (1991) <i>J. Neurology, Neurosurgery, and Psychiatry</i> 54:388-396
37	Glinka, Y.Y. and Youdim, M.B.H., "Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine," (1995) <i>Eur. J. Pharmacology Environ. Toxicol. Pharmacol. Section 292</i> , 329-332
38	Glinka, Y. et al., "Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine," (1996) <i>J. Neurochemistry</i> 66(5):2004-2010
39	Golbe, L.I., "Alpha-synuclein and Parkinson's disease," (1999) <i>Movement Disorders</i> 14(1):6-9
40	Goldstein, M. and Lieberman, A., "The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease," (1992) <i>Neurology</i> 42(S4):8-12
41	Gotham, A.M. et al., "Levodopa treatment may benefit or impair 'frontal' function in Parkinson's disease," (1986) <i>Lancet</i> 25;2(8513):970-971
42	Graham, D., "Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease," (1984) <i>Toxicology</i> 5(1):83-96
43	Graham, D.G., "Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones," (1978) <i>Molecular Pharmacology</i> 14:633-643
44	Graham, D.G., "Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells <i>in vitro</i> " (1978) <i>Molecular Pharmacology</i> 14:644-653
45	Hall, S. et al., "MRI, brain iron and experimental Parkinson's disease," (1992) <i>J. Neurological Sci.</i> 198-208
46	Hirsch, E. et al., "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease," (1988) <i>Nature</i> 334:345-348
47	Hirsch, E.C. and Faucheux, B.A., "Iron metabolism and Parkinson's disease," (1998) <i>Movement Disorders</i> 13(S1):39-45
48	Ivanina, T.A. et al., "A study of the mechanisms of chloroquine retinopathy," (1989) <i>Ophthalmic Res.</i> 21:216-220
49	Ivanova, S. et al., "Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death," (1998) <i>J. Exp. Med.</i> 188(2):327-340
50	Jackson, M.J. et al., "Inhibition of lipid peroxidation in muscle homogenates by phospholipase A2 inhibitors," (1984) <i>Bioscience Reports</i> 4(7):581-587 (abstract only)

Wagner

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

✓	51	Jenner, P., "Oxidative stress in Parkinson's disease and other neurodegenerative disorders," (1996) <i>Pathologie Biologie</i> 44(1):57-64
✓	52	Jenner, P. et al., "Understanding cell death in Parkinson's disease," (1998) <i>Annals of Neurology</i> 44(1):S72-S84
	53	Karmazyn, M. et al., "The mechanism of coronary artery spasm: roles of oxygen, prostaglandins, sex hormones and smoking," (1979) <i>Medical Hypothesis</i> 5:447-452
	54	Kienzl, E. et al., "Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?" (1999) <i>Life Sci</i> 65(18-19):1973-1976
	55	Koller, W.C., "When does Parkinson's disease begin?", (1992) <i>Neurology</i> 42(S4):27-31
	56	Krogstad, D.J. and Schlesinger, P.H., "Acid-vesicle function, intracellular pathogens, and the action of chloroquine against <i>plasmodium falciparum</i> ," (1987) <i>N.E. J. Med.</i> 317(9):543-549
	57	Langston, J.W. et al., "Pargyline prevents MPTP-induced Parkinsonism in primates," (1984) <i>Science</i> 225:1480-1482
	58	Langston, J.W., "MPTP neurotoxicity: an overview and characterization of phases of toxicity," (1985) <i>Life Sciences</i> 36:201-206
	59	Larsson, B. and Tjälve, H., "Studies on the mechanism of drug-binding to melanin," (1979) <i>Chemical Pharmacology</i> 28:1181-1187
	60	Leahy, F. et al., "Desquamative interstitial pneumonia responsive to chloroquine," (1985) <i>Clinical Pediatrics</i> 24(4):230-232
	61	Legssyer, R. et al., "Effect of chronic chloroquine administration on iron loading in the liver and reticuloendothelial system and on oxidative responses by the alveolar macrophages," (1999) <i>Biochem. Pharmacology</i> 57(8):907-911
	62	Lieberman et al., "Does selegiline provide a symptomatic or a neuroprotective effect?", (1992) <i>Neurology</i> 42(S4):41-48
	63	Lin, A.M-Y et al., "Striatal dopamine dynamics are altered following an intranigral infusion of iron in adult rats," (1998) <i>Free Radical Biology & Medicine</i> 24(6):988-993
	64	Linnik, M.D. et al., "Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats," (1993) <i>Stroke</i> 24(12):2002-2009
	65	Loo, D.T. et al., "Apoptosis is induced by β -amyloid in cultured central nervous system neurons," (1993) <i>Proc. Natl. Acad. Sci. USA</i> 90:7951-7955
✓	66	Lyden, A. et al., "Studies on the melanin affinity of haloperidol," (1982) <i>Arch. Int. Pharmacodyn. Ther.</i> 259(2):230-243

Wayne C. Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

67	Magwere, T. et al., "Effects of chloroquine treatment on antioxidant enzymes in rat liver and kidney," (1997) <i>Free Radical Biology & Medicine</i> 22(1-2):321-327
68	Makarenko, I.E. and Levitsky, E.P., "Resoquin in the clinic of internal illnesses, and the possible side effects of its use," (1950)
69	Maret, G. et al., "The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing Parkinsonism," (1990) <i>Drug Metabolism Reviews</i> 22(4):291-332
70	Martin, W.R.W. et al., "Increasing striatal iron content associated with normal aging," (1998) <i>Movement Disorders</i> 13(2):281-286
71	Matsubara, K. et al., "Beta-carbolinium cations, endogenous MPP ⁺ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's," (1995) <i>Neurology</i> 45(12):2240-2245
72	Meerson, F.Z. et al., "Prevention of stress disorders of myocardial contractile function using membrane protectors," (1983) <i>Kardiologiya</i> 23(7):86-90 (abstract and translation in English)
72A	Mena, M.A., "Pharmacokinetics of L-DOPA in patients with Parkinson's Disease," (1986) <i>Advances in Neurology</i> 45:481-486
73	Merad-Boudia, M. et al., "Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease," (1998) <i>Biochem. Pharmacology</i> 56:645-655
74	Mielke, J.G. et al., "Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction," (1997) <i>Neuroscience Lett.</i> 227(3):169-172
74A	Minotti, G. and Aust, S.D., "The requirement for iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide," (1987) <i>J. Biological Chemistry</i> 262(3):1-98-1104
75	Mizuno, Y. et al., "Mitochondrial dysfunction in Parkinson's disease," (1998) <i>Annals of Neurology</i> 44(S1):S99-S109
76	Monteiro, H.P. and Winterbourn, C.C., "6-hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation," (1989) <i>Biochem. Pharm.</i> 38(23):4177-4182
77	Mytilineou, C. et al., "L-(—)-desmethylselegiline, a metabolite of selegiline [L-(—)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro," (1997) <i>J. Neurochemistry</i> 68(1):434-436
78	Navas, P. et al., "Decrease of NADH in HeLa cells in the presence of transferrin or ferricyanide," (1986) <i>Biochem. and Biophys. Res. Communications</i> 135(1):110-115

Wagner C. Jones

2/24/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

79	Nicklas, W.J. et al., "Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine," (1985) <i>Life Sciences</i> 36:2503-2508
80	Okamoto, M. et al., "Internucleosomal-DNA cleavage involved in ischemia-induced neuronal death," (1993) <i>Biochem. and Biophys. Res. Communications</i> 196(3):1356-1362
81	Octave, J-N et al., "Iron uptake and utilization by mammalian cells. I: Cellular uptake of transferrin and iron," (1983) <i>TIBS</i> 217-220
82	Olanow, C.W. and Calne, D., "Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?" (1992) <i>Neurology</i> 42(S4):13-26
83	Ornstein, M.H. and Sperber, K., "The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis," (1996) <i>Arthritis Rheum.</i> 39(1):157-161
84	Poewe, W.H. and Wenning, G.K., "The natural history of Parkinson's disease," (1998) <i>Annals of Neurology</i> 44(S1):S1-S9
85	Pratt, W.B. and Fekety, R., "Chemotherapy of malaria," <i>The Antimicrobial Drugs</i> , (1986) Oxford University Press, New York, Chapter 14:355-384
86	Remblier, C. et al., "Lactic acid-induced increase of extracellular dopamine measured by microdialysis in rat striatum: evidence for glutamatergic and oxidative mechanisms," (1999) <i>Brain Research</i> 837:22-28
87	Riederer, P. et al., "Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains," (1989) <i>J. Neurochemistry</i> 52(2):515-520
88	Rollema, H. et al., "In vivo intracerebral microdialysis studies in rats of MPP ⁺ analogues and related charged species," (1990) <i>J. Med. Chem.</i> 33:221-2230
89	Rollema, H. et al., "MPP ⁺ -like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies," (1994) <i>J. Pharm. and Exp. Therapeutics</i> 268(1):380-387
89A	Rollema, H. et al., "Comparison of the effects of intracerebrally administered MPP ⁺ (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat and monkey striatum," (1989) <i>Neuroscience Letters</i> 106:275-281
90	Roos, R.A. et al., "Response fluctuations in Parkinson's disease," (1990) <i>Neurology</i> 40(9):1344-1346
91	Schapira, A.H., "Oxidative stress in Parkinson's disease," (1995) <i>Neuropathol. Appl. Neurobiol.</i> 21(1):3-9

Wagner C. Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

92	Spencer, J.P.E. et al., "Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease," (1995) <i>NeuroReport</i> 6:1480-1484
93	Sperber, K. et al., "Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1," (1995) <i>Clinical Therapeutics</i> 17(4):622-636
94	Springer, C. et al., "Chloroquine treatment in desquamative interstitial pneumonia," (1987) <i>Archives of Disease in Childhood</i> 62:76-77
95	Stepien, K.B. and Wilczok, T., "Studies of the mechanism of chloroquine binding to synthetic DOPA-melanin," (1982) <i>Biochem. Pharmacol.</i> 1;31(21):3359-3365
96	Stoof, J.C. et al., "Leads for the development of neuroprotective treatment in Parkinson's disease and imaging methods for estimating treatment efficacy," (1999) <i>Eur. J. Pharmacol.</i> 375(1-3):75-86
97	Swaiman, K.F. and Machen, V.L., "Chloroquine reduces neuronal and glial iron uptake," (1986) <i>J. Neurochemistry</i> 46(2):652-654
98	Tipton, K.F. and Singer, T.P., "Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds," (1993) <i>J. Neurochem.</i> 61(4):1191-1206
99	Tjalve, H. et al., "Studies on the binding of chlorpromazine and chloroquine to melanin in vivo," (1981) <i>Biochem. Pharmacol.</i> 30(13):1845-1847
100	Toole-Simms, W. et al., "Transplasma membrane electron and proton transport is inhibited by chloroquine," (1990) <i>Biochem. International</i> 21(4):761-769
101	Vainshtok, A.B., "Treatment of Parkinsonism with delagil," (1972) <i>Klin. Med (Mosk)</i> 50(9):51-56
102	Yong, V.W. et al., "Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment," (1986) <i>Neuroscience Letters</i> 63:56-60
103	Youdim, M.B.H. et al., "Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?", (1989) <i>Acta Neurol. Scand.</i> 126:47-54
104	<u>Biochemistry</u> , (1975) Lubert Stryer, Stanford University, W.H. Freeman and Company, San Francisco, CA
105	"Chloroquine", Micromedex Healthcare Series, http://phantom.uchsc.edu/mdxcgi/di....SYS&SET=485440&SYS=1&T=358&D=1692

Wagner Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in 09/615,639

	106	<u>Clinical Toxicology of Commercial Products</u> (1984) Gosselin, Smith, Hodge, 5 th Ed., Williams & Wilkins, Baltimore/London, II-245
	107	<u>Diagnostic Clinical Neuropsychology</u> (1997) Bigler, E. and Clement, P., 3 rd Ed., University of Texas Press, Austin, TX
	108	<u>Fundamentals of Anatomy & Physiology</u> (1995) Martini, Frederic H., 3 rd Ed., Prentice Hall, Englewood Cliffs, NJ
	109	<u>The Merck Index</u> , (1996) 12 th Ed., Susan Budavari, Ed., Merck Research Laboratories, Inc., Whitehouse Station, NJ, "Chloroquine - 7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline," p. 2220
	109 A	<u>The Merck Index</u> , (1960) 7 th Ed., P.G. Stecher, Ed., Merck & Co., Inc. Rahway, NJ
	110	<u>Organic Chemistry</u> , (1996) McMurry, John, 4 th Ed., Brooks/Cole Publishing, an International Thomson Publishing Co., Pacific Grove, CA
	111	<u>Physicians' Desk Reference</u> , (1996) 50 th Ed., Medical Economics Company, Inc., Montvale, NJ
	112	<u>Physicians' Desk Reference</u> , (2000) 54 th Ed., Medical Economics Company, Inc., Montvale, NJ
	113	"Practical chemotherapy of Malaria," (1990) World Health Org. Technical Report Series No. 805, p. 141
	113 A	<u>Russian Drug Index</u> , 2d Ed., S. Jablonski, US Dept. HEW, Public Health Service Publication No. 814 (Revised 1967)
	114	<u>Textbook of Medical Physiology</u> (1996) Guyton, A.C. and Hall, J.E., 9 th Ed., W.B. Saunders Company, Philadelphia, PA

EXAMINER	DATE CONSIDERED
<i>Wayne Jones</i>	2/2/06
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

12/20/89



Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in USSN 09/615,639

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	6,015,555	01/18/00	Friden (abstract only)	424	133.1	
	5,948,791	09/07/99	Hofheinz et al.	514	313	
	5,834,505	11/10/98	Peters	514	454	
	5,736,556	04/07/98	Moldt et al.	514	304	
	5,639,737	06/17/97	Rubin	514	53	
	5,624,938	04/29/97	Pernis	514	313	
	5,596,002	01/21/97	Hofheinz et al.	514	313	
	5,430,039	07/04/95	Roberts-Lewis et al.	514	297	
	5,210,076	05/11/93	Berliner et al.	514	21	
	4,421,920	12/20/83	Baudouin et al.	546	163	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes/No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)



		Augustijns, P. et al., "Stereoselective de-ethylation of chloroquine in rat liver microsomes," (1999) <i>Eur. J. Drug Metabolism & Pharmacokinetics</i> 24(1):105-108 (abstract only)
		Augustijns, P. and Verbeke, N., "Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans," (1993) <i>Clin. Pharmacokinetics</i> 24(3):259-269 (abstract only)
		Begley, D.J., "The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system," (1996) <i>J. Pharm. Pharmacol.</i> 48(2):136-146
		De Boer, A.G. and Breimer, D.D., "The blood-brain barrier: clinical implications for drug delivery to the brain," (1994) <i>J. R. Coll. Physicians Lond.</i> 28(6):50-506


Wayne C. Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT Nelson		GROUP 1614

Originally filed in USSN 09/615,639

		Donatelli, P. et al., "Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain," (1994) <i>Eur. J. Clin. Pharmacol.</i> 47(4):345-349 (abstract only)
		Ducharme, J. et al., "Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects," (1995) <i>Brit. J. Clin. Pharmacol.</i> 40(2):127-133 (abstract only)
		Ducharme, J. and Farinotti, R., "Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advances," (1996) <i>Clin. Pharmacokinet.</i> 31(4):257-74 (abstract only)
		Scaria, P.V. et al., "Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism," (1993) <i>Biopolymers</i> 33(6):887-95 (abstract only)
		Tago, C.N. and Ofori-Adjei, D., "Effects of chloroquine and its enantiomers on the development of rat embryos in vitro," (1995) <i>Teratology</i> 52(3):137-142 (abstract only)
		Yatin, S.M. et al., "Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E," (1999) <i>Neuroscience Letters</i> 263(1):17-20 (abstract only)

EXAMINER 	DATE CONSIDERED 2/21/06
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

12/20/89



Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

Originally cited in 09/615,639

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>JN</i>	5,154,924	10/13/02	Friden	424	85.91	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes/No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

<i>JN</i>		Ambrozi et al. (1976) "L-Dopa and (-)-deprenil in the treatment of Parkinson's disease: long-term study," <i>Br. J. Pharmacol.</i> 58(3):423-424. Database CA on STN. Chem. Abstr., Vol. 86 (Columbus OH USA), abstract No. 133721
		Golbe et al. (1993) "Vitamin E and Parkinson's disease," <i>Vitam. E Health Dis.</i> , Packer et al. Eds., Dekker, New York, NY, pp. 787-797, Database CA on STN. Chem. Abstr., Vol. 119 (Columbus, OH, USA) abstract No. 71356
		Hemmer et al. (1967) "Cerebral activity of an herbal preparation (Tebonin) from Ginko biloba," <i>Arzneim-Forsch.</i> 17(4):491-493, Database CA on STN. Chem. Abstr., Vol. 67 (Columbus, OH, USA) abstract No. 52644

EXAMINER <i>W. J. [Signature]</i>	DATE CONSIDERED <i>2/2/06</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

12/20/89

ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

Cited by Examiner in 09/615,639

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes/No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

H			Montrastruc JL, 1991. Therapie, 46(4):293-303. Recent advances in the clinical pharmacology of Parkinson's disease.
			Lowrey BS, 1997, Pigment Cell Res. vol. 10(5):251-256. Modeling drug-melanin interaction with theoretical linear solvation energy relationships.
			Paramar RC et al. 2000, J. Postgrad Med. 46(1):29-30. Chloroquine induced parkinsonism.
			Webster et al., Biochem. Pharmacol. 1991, Vol. 42, pages S225-7. Antimalarial activity of optical isomers of quinacrine dihydrochloride against chloroquine-sensitive and resistant plasmodium faciparum <i>in vitro</i> .
✓			Haberkorn A et al., Tropenmed. Parasitol. 1979, Vol. 30, pages 308-312. Antimalarial activity of the optical isomers of chloroquine diphosphate.

EXAMINER <i>Wayne Jones</i>	DATE CONSIDERED <i>2/2/06</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

12/20/89



Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

Originally filed in 09/615,639

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes/No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

u		Aisen, Paul S. (1997) "Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Strategies," <i>Gerontology</i> 43:143-149
		Bhatia, M.S. (1991), "Chloroquine-induced psychiatric complications," <i>British Journal of Psychiatry</i> 159(Nov):735 (Abstract)
		Bhatia, M.S. et al. (1988), "Capgras syndrome in chloroquine induced psychosis," <i>Indian Journal of Psychiatry</i> 30(3):311-313 (Abstract)
		Cockroft, K M. et al. (1996) "Cerebroprotective effects of aminoquanidine in a rodent model of stroke," <i>Stroke</i> 27(8):1393-1398
		Conference Proceedings, Stroke Drug Development: Bridging the Gap From Animal Research to Human Trials, March 6-7, 1999, Orlando, FL, Proceedings Transcripts, Side 2, #10
		Donatelli, P. et al. (1994) "Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain," <i>Eur. J. Clin. Pharmacol.</i> 47:345-349
		Feuerstein, G.Z. and Wang, X. (2000) "Animal models of stroke," <i>Molecular Medicine Today</i> 6:133-135
		Garg, P. et al. (1990) "Toxic psychosis due to chloroquine - not uncommon in children," <i>Clinical Pediatrics</i> 29(8):448-450
		Golden, G.T. (1992) "Systemic chloroquine protects against striatal dopamine depletion induced by unilateral intra-nigral MPP+ injection in rats," <i>Soc. Neurosci.</i> (Abstract); letter from Dr. G.M. Alexander in regard thereto.
v		Good, M.I. and Shader, R.I. (1997) "Behavioral toxicity and equivocal suicide associated with chloroquine and its derivatives," <i>Am. J. Psychiatry</i> 134(7):798-801

Wynne Jones

2/21/06

Form PTO 1449		
ATTY DOCKET NO. 47-00B	SERIAL NO. 10/616,692	FILING DATE July 9, 2003
APPLICANT J. Nelson		GROUP 1614

Originally filed in 09/615,639

		Good, M.I. and Shader, R.I.(1982) "Lethality and behavioral side effects of chloroquine," <i>J. Clin. Psychopharmacology</i> 2:40-46
		Hagihara, N. et al. (2000) "Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107," <i>Cancer Res.</i> 60:230-234
		Lovestone, S. (1991), "Chloroquine-induced mania," <i>British Journal of Psychiatry</i> 159(Jul):164-165 (Abstract)
		Lowrey, A.H. et al., (1997) "Modeling Drug-melanin Interaction with Theoretical Linear Solvation Energy Relationships," <i>Pigment Cell Res.</i> 10 251-256
		Ofori-Adjei, D. et al. (1986) "Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine," <i>Therapeutic Drug Monitoring</i> 8:457-461
		Ofori-Adjei, D. et al. (1986) "Protein binding of chloroquine enantiomers and desethylchloroquine," <i>Br. J. Clin. Pharmac.</i> 22:356-358
		Rosner, P.I. and Legros, J. (1967) "Hydroxychloroquine et resistance corticale a l'anoxie asphyxique," <i>Therapie XXII</i> :355-360
		Sharma, O.P. (1998) "Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement," <i>Archives of Neurology</i> 55(9):1248-1254
		Shields, D.C. et al., (1999) "A putative mechanism of demyelination in multiple sclerosis by proteolytic enzyme, calpain," <i>Proc. Natl. Acad. Sci. USA</i> 96:11486-11491
		Tedeschi, M. (1983), "A case of acute psychosis due to Chloroquine," <i>Information Psychiatrique</i> 59(9):1191-1197 (Abstract)
		Webster, R.V. et al. (1991) "Antimalarial activity of optical isomers of quinacrine dihydrochloride against chloroquine-sensitive and -resistant <i>Plasmodium falciparum</i> in vitro," <i>Biochem. Pharm.</i> 42:S225-S227

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	2/21/06
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

12/20/89

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/616,692
Filing Date	July 9, 2003
First Named Inventor	Nelson, Jodi
Art Unit	1614
Examiner Name	Unassigned J. C. JWCs
Attorney Docket Number	47-00B

GWS 6/27/2005

U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ben-Shachar, D. et al. (1993), "Iron, melanin and dopamine interaction: Relevance to Parkinson's disease," Progress in Neuro-Psychopharmacology and Biological Psychiatry, 17(1):139-150.	
		D'Ischia Marco et al. (1997) "Biosynthesis, structure and function of neuromelanin and its relation to Parkinson's disease: a critical update," Pigment Cell Research 110(6):370-376.	
		Garcia Ruiz, P.J., et al. (1992), "Cinnarizine-induced parkinsonism in primates," Clinical neuropharmacology 15(2):152-154 (Abstract)	
		Garcia-Ruiz, P.J., et al. (1992) "Parkinsonism associated with calcium channel blockers: a prospective follow-up study," Clinical Neuropharmacology 15(1):19-26 (Abstract)	
		Geddes, J.F., et al. (1993), "Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex," Brain, (Pt 1):281-302 (Abstract).	
		Hayase, Y, et al. (1997), "Influenza virus and neurological diseases," Psychiatry Clin. Neurosci. 41(4):181-4 (Abstract).	
		Kuzuhara S., et al. (1989), "Parkinsonism, depression and akathisia induced by flunarizine, a calcium entry blockade-report of 31 cases," Rinsho shinkeigaku (Japan) 29 (6):681-686 (Abstract)	

Examiner Signature	<i>[Signature]</i>	Date Considered	6/27/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).




²Applicant is to place a check mark here or "x" if English language Translation is attached.


Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/616,692
Filing Date	July 9, 2003
First Named Inventor	Nelson, Jodi
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	47-00B

GWS 6/27/2005

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Majno, G. et al. (1995), "Apoptosis, Oncosis, and Necrosis, An overview of Cell Death," American J. Pathology 146(1):3-16.	
		Negrotti, A. et al. (1992), "Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility," Neurotoxicology 13(1):261-4 (Abstract)	
		Savenko, S.N., et al. (1975), "Histamine metabolism in patients with cerebral circulatory disorders together with hypertension and cerebral atherosclerosis," Zh Nevropatol Psikhiatr Im S S Korsakova 75(8):1162-7 (Abstract)	
		Takahashi, A., et al. (1993), "Drug-induced movement disorders," Nippon rinsho (JAPAN) 51(11):2929-34 (Abstract)	
		Tatton, N.A., et al. (Sept. 1998), "A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease," Annals of Neurology 44(3 Suppl 1):S142-148 (Abstract)	
		Tatton, W.G., et al. (Sept., 1998), "Mitochondria in Neurodegenerative Apoptosis: an Opportunity for Therapy?" Annals of Neurology 44(3 Suppl. 1): S134-41 (Abstract)	

Examiner Signature		Date Considered	2/21/06
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/616,692
Filing Date	09/07/2003
First Named Inventor	Nelson
Art Unit	1614
Examiner Name	Unassigned D. C. JONES
Attorney Docket Number	47-00B

GWS 12/12/2005

U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)
	1	5,496,836	03/05/1996	Di Rocco et al.	
	2	5,352,688	10/04/1994	Kaminski	

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	ABIOSE, A.K., et al., Chloroquine-induced venodilation in human hand veins; <i>Clinical Pharmacology & Therapeutics</i> , June 1997, Vol. 61, No. 6, 677-683.	
	4	ADLER, L.E., et al., Cimetidine Toxicity Manifested as Paranoia and Hallucinations; <i>Am J Psychiatry</i> , Sept. 1980, 137:9, 1112-1113.	
	5	BATEMAN, D. N., et al., Cimetidine induced postural and action tremor; <i>J Neurol Neurosurg Psychiatry</i> , Jan. 1981, 44(1):94.	
	6	AMABEOKU, G. J., Some behavioural effects of chloroquine in rats suggesting dopaminergic activation; <i>Indian J Med Res.</i> , Feb. 1994, 99:87-94.	
	7	BYRON, J. W., Mechanism for Histamine H ₂ -Receptor Induced Cell-Cycle Changes in the Bone Marrow Stem Cell; <i>Agents & Actions</i> , Jul. 1977, 7(2):209-13.	
	8	DONATELLI, P., et al., Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain; <i>Eur J Clin Pharmacol.</i> , 1994, 47(4):345-9, abstract only.	
	9	ETTE, E.I., et al., Effect of ranitidine on chloroquine disposition; <i>Drug Intell Clin Pharm.</i> , Sept. 1987, 21(9):732-4.	
	10	GARCIA-RUIZ, P.J., et al., Cinnarizine-induced parkinsonism in primates; <i>Clinical Neuropharmacology</i> , Apr 1992, 15(2):152-4, abstract only.	

Examiner Signature	<i>Walter Jones</i>	Date Considered	2/2/06
--------------------	---------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

Sheet 2 of 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Substitute for form 1449/PTO, based on PTO/SB/08A and 08B	Application Number	10/616,692
		Filing Date	09/07/2003
		First Named Inventor	Nelson
		Art Unit	1614
		Examiner Name	Unassigned <i>D.C. Jarvis</i>
		Attorney Docket Number	47-00B

GWS 12/12/2005

Examiner Initial*	Cite No. ¹	REFERENCE	T ²
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
<i>[Signature]</i>	11	GARCIA-RUIZ, P.J., et al., Parkinsonism associated with calcium channel blockers: a prospective follow-up study, <i>Clinical Neuropharmacology</i> , Feb. 1992, 15(1):19-26, abstract only.	
<i>[Signature]</i>	12	HANDLER, C. E., et al., Extrapyramidal and cerebellar syndrome with encephalopathy associated with cimetidine; <i>Postgrad Med Journal</i> , Aug. 1982, 58:527-528.	
<i>[Signature]</i>	13	HARLE, D.G., et al., Structural features of potent inhibitors of rat kidney histamine N-methyltransferase; <i>Biochem Pharmacol.</i> , Feb. 1988, 37(3):385-8, abstract only.	
<i>[Signature]</i>	14	HUTCHISON, T. A., et al., Comparative Dosage Table – Histamine H2 Receptors; <i>Drugdex® System</i> , 2000.	
<i>[Signature]</i>	15	KUSHNER, M. J., Chorea and Cimetidine; <i>Annals of Internal Medicine</i> , Jan. 1982, 96(1):126.	
<i>[Signature]</i>	16	KUZUHARA, S., et al., Parkinsonism, depression and akathisia induced by flunarizine, a calcium entry blockade – report of 31 cases; <i>Shinkeigaku (Japan)</i> , June 1989, 29(6):681-6, abstract only.	
<i>[Signature]</i>	17	LEHMANN, A. B., Reversible Chorea Due to Ranitidine and Cimetidine; <i>The Lancet</i> , July 1988, 2(8603):158.	
<i>[Signature]</i>	18	LOT, T. Y., The effects of chronic administration of chloroquine and quinacrine on the response of normal and denervated smooth muscle to agonist drugs; <i>Physiol Behav.</i> , Aug. 1993, 54(2):345-9, abstract only.	
<i>[Signature]</i>	19	McMAHON, T., Dyskinesia associated with amoxapine withdrawal and use of carbamazepine and antihistamines; <i>Psychosomatics</i> , Feb. 1986, 27(2):145-148.	
<i>[Signature]</i>	20	NEGROTTI, A., et al., Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility, <i>Neurotoxicology</i> , Spring 1992, 13(1):261-264, abstract only.	
<i>[Signature]</i>	21	POIRIER, J., et al., Debrisoquine Metabolism in Parkinsonian Patients Treated with Antihistamine Drugs, <i>The Lancet</i> , Aug. 1987, p. 386.	
<i>[Signature]</i>	22	PORTER, J. B., et al., Intensive Hospital Monitoring Study of Intravenous Cimetidine, <i>Arch Intern Med</i> , Nov. 1986, 146:2237-9.	
<i>[Signature]</i>	23	TAKAHASHI, A., et al., Drug-induced movement disorders; <i>Nippon rinsho (Japan)</i> , Nov. 1993, 51(11):2929-34, abstract only.	
<i>[Signature]</i>	24	TOTTE, J., et al., Neurological Dysfunction Associated with Abnormal Levels of Cimetidine Metabolite, <i>The Lancet</i> , May 1981, 1(8228):1047.	
<i>[Signature]</i>	25	Micro Medex website, DRUGDEX® Drug Point, Drug Point® Summary, FAMOTIDINE, printout Dec. 2005	
<i>[Signature]</i>	26	Micro Medex website, CIME Adult Dosages, printout Dec. 2005	
<i>[Signature]</i>	27	Micro Medex website, CQ Precautions, printout Dec. 2005	
<i>[Signature]</i>	28	Micro Medex website, CIME – Neurological AEs, printout Dec. 2005	

Examiner Signature	<i>[Signature]</i>	Date Considered	
--------------------	--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/616,692
Filing Date	July 9, 2003
First Named Inventor	Nelson, Jodi
Art Unit	1614
Examiner Name	Unassigned <i>D.C. Jones</i>
Attorney Docket Number	47-00 B

GWS 9/20/2005

U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)
<i>M</i>	1	5,496,836	03/05/1996	Di Rocco et al.	7 pages

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature	<i>Walter Jones</i>	Date Considered	2/21/06
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.